Citations

Clear

1417 citation(s) found for "Li, Simon".

Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study
Alouani, Emily , Tougeron, David , Roces, Guillaume, Pernot, Simon , Dutherage, Marie, Cohen, Romain , Hafliger, Émilie , Sclafani, Francesco , Masson, Thérèse, Coutzac, Clélia , Mazard, Thibault , Jaffrelot, Marion, Guimbaud, Rosine , Sèlves, Janick , Taieb, Julien , Tougeron, David , Cohen, Romain , Coutzac, Clélia , Taı̈eb, Julien , Hollebecque, Antoine , Parent, Pauline , Sinicrope, Frank A. , Hautefeuille, Vincent , Abdelghani, Méher Ben , Müller, Marie , Perkins, Géraldine , Aparicio, Thomas , Decraecker, Marie

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 30, 2025 | Volume: 13 | Issue: 10 | Pages: e011436

10.1136/jitc-2024-011436 | PMID 41167636 Get It

Background Tumors with mismatch repair deficiency (MMRd) classically display concomitant loss of MLH1/PMS2 or MSH2/MSH6 on immunohistochemistry (IHC) with microsatellite instability-high (MSI-High) status on molecular testing. Nevertheless, a different phenotype can occur in up to 15% of MMRd tumors (unusual phenotype). Data on the efficacy of immunotherapy in this population remain scarce. Methods We conducted a retrospective study within the IMMUNODIG MSI cohort including patients with advanced gastrointestinal MMRd tumors treated with immune checkpoint blockade in the real-world setting. We selected patients with both IHC and MSI assays data available. Unusual MMRd tumors were classified into four distinct groups: (1) isolated loss of PMS2 or MSH6 with MSI-H (isolated/MSI-H), (2) complex loss of MMR proteins with MSI-H (complex/MSI-H), (3) loss of one or more MMR proteins without MSI-H (MMRd-IHC/microsatellite stability (MSS) or MSI-low (MSI-L)), and (4) four MMR proteins retained with MSI-H (retained IHC/MSI-H). Results Out of 759 patients in the IMMUNODIG-MSI cohort, 571 patients met inclusion criteria. Of these, 90 (15.8%) had an unusual phenotype (47 isolated/MSI-H, 19 complex/MSI-H, 16 MMRd-IHC/MSS or MSI-L and 8 retained IHC/MSI-H). Compared with classical phenotypes, patients with a tumor harboring an unusual phenotype had a younger age at treatment (p=0.005), increased RAS mutation (p=0.005), reduced BRAF p.V600E mutation rates (p<0.001), a higher proportion of Lynch syndrome (p<0.001) and a higher prevalence of non-colorectal cancers (p=0.021). After a median follow-up of 28.1 months (mo), there was a significant difference in progression-free survival, with median values of not reached, 66.4 mo, 37.2 mo, 18.3 mo and 5.5 mo for complex/MSI-H, isolated/MSI-H, classical, retained IHC/MSI-H and MMRd-IHC/MSS or MSI-L subgroups, respectively (p<0.001). Notably, objective response rates were 59.1%, 58.7%, and 63.2% for complex/MSI-H, isolated/MSI-H and classical contrasting with 50% and 25% for retained IHC/MSI-H and MMRd-IHC/MSS or MSI-L, with no complete response observed in the latter two. Conclusion Our findings underscore the need for dual testing and advocate for the presence of both MMRd-IHC and MSI-H for optimal immunotherapy response. Of note, complex MMR aberrations and isolated PMS2/MSH6 losses with MSI-H may represent promising candidates for enhanced immunotherapy efficacy.
Consensus-Based Definitions for Vocal Biomarkers: The International VOCAL Initiative
Au, Rhoda , Toghranegar, Jamie , Bahr, Ruth Huntley , Pizzimenti, Megane , Kalia, Ayush , Toghranegar, Jamie A , Ebraheem, Mohamed , Cummins, Nicholas , Ghosh, Satrajit S , Anibal, James T , Au, Rhoda , Azarang, Arian , Bahr, Ruth H , Bedrick, Steven D , Botha, Hugo , Coleman, Oita C , Elbeji, Abir , Kourtis, Lampros C , Rameau, Anais , Sara, Jaskanwal D S , Watts, Stephanie , Hemmerling, Daria , Mekyska, Jiri , Speights, Marisha L , Belisle-Pipon, Jean-Christophe , Bensoussan, Yael , Fagherazzi, Guy , Bedrick, Steven , Botha, Hugo , Sara, Jaskanwal Deep Singh , Hemmerling, Daria , Speights, Marisha L., (CA24128), the eVoiceNet COST Action, Bensoussan, Yaël

Mayo Clinic

No container title available | October 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.10.23.25338518 | PMID 41404273 Get It

Abstract Importance Voice-based health technologies are growing rapidly, but they lack standardized terminology, which hinders interdisciplinary collaboration, research quality, and clinical translation. Objective The objective of this work is to develop universally accepted definitions in the rapidly evolving field of vocal biomarkers, as part of the VOCAL ( V ocal Biomarker Guidelines for O ntology, C lassification, A pplication, and L ogistics) initiative, a structured, international consensus-based framework that aims to provide standards, and guidelines. Design VOCAL is a rigorous, international, multi-stage consensus-building study conducted in 2024-2025. Setting Multi-institutional collaboration between representatives from the Bridge2AI-Voice Consortium (North America) and the eVoiceNet Network (European Union), culminating in an in-person workshop at the 2025 Bridge2AI Voice Symposium. Participants A group of 24 international experts in medicine, clinical research, speech and language, audio signal processing, statistics, methodology, regulation, ethics. Methods VOCAL’s iterative process involved five rounds of review, feedback, and an in-person workshop at the international 2025 Bridge2AI Voice Symposium, ensuring the incorporation of diverse perspectives and achieving a robust agreement on the proposed definitions. Main outcomes and measures Consensus-based definitions for vocal biomarkers, spanning from broad concepts (biomarker, digital biomarker, vocal biomarker) to domain-specific measures (cardio-respiratory acoustic, voice, speech/articulatory, cognitive/language). Results A hierarchical continuum model of vocal biomarkers was established. We first distinguished between the concepts of vocal measures and vocal biomarkers. We then defined terms from broad, overarching concepts (Level 0: Biomarker, Digital Biomarker, Vocal Biomarker) to more specific physiological and cognitive domains (Level 1: Cardio-Respiratory Acoustic; Level 2: Voice; Level 3: Speech/Articulatory; Level 4: Cognitive/Language, including linguistic and paralinguistic subtypes). Conclusions and Relevance This work provides a shared vocabulary that is essential for fostering communication through interdisciplinary collaboration, improving the quality and efficiency of research and development, and ensuring the ethical, reliable, and scalable deployment of future voice-based health technologies. It lays foundational groundwork for upcoming guidelines and standards, which are crucial for advancing the field of vocal biomarkers into widespread clinical utility. Key points Question Can we establish an international consensus on the definitions related to vocal biomarkers? Findings Through a multi-stage international consensus process involving expert representatives from the Bridge2AI-Voice Consortium and eVoiceNet Network, a hierarchical model of vocal biomarkers was developed, defining terms from broad concepts (biomarker, digital biomarker, vocal biomarker) to specific physiological and cognitive domains (cardio-respiratory acoustic, voice, speech/articulatory, cognitive/language). Meaning Standardized definitions for vocal biomarkers provide an essential shared vocabulary for interdisciplinary collaboration and lay the foundational groundwork for future guidelines needed to advance the implementation of voice-based health technologies into clinical practice and clinical research.
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Zhu, Ling , Cheung, Yee-Ming Melody , Mammen, Jennifer S. , Quandt, Zoe , Jones, Renisha, McDunn, Jon, Al-Bahadili, Huda , Warner, Allison Betof , Blackwell, Susan, Cho, Tracey , Dougan, Michael , Funchain, Pauline , Johnson, Douglas B. , Kennedy, Randol , Lim, Annette M. , Overton, Laura, Perdigoto, Ana Luisa , Sachithanandan, Nirupa , Spain, Lavinia , Tsai, Katy K., Reynolds, Kerry L. , Shariff, Afreen , Quandt, Zoe , Betof Warner, Allison , Funchain, Pauline , Herndon, Justine , Lim, Annette M , Tsai, Katy , Reynolds, Kerry L , Cho, Tracey A , Chiang, Cherie Ying , Gallagher, Emily J. , Hamnvik, Ole‐Petter R. , Jones, Renisha, McDunn, Jon , Angell, Trevor E. , Bancos, Irina , Calabrese, Cassandra M. , Ferreira, Michelle , Kheterpal, Meenal , Khouri, Michel G. , Lechner, Melissa G , Markova, Alina , Meara, Alexa Simon , Overton, Laura, Sharon, Elad , Yarchoan, Mark

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 15, 2025 | Volume: 13 | Issue: 10 | Pages: e011865

10.1136/jitc-2025-011865 | PMID 41093625 Get It

Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and timely can be challenging in the absence of clear categorization and standardization across oncology, endocrinology and other specialties. While existing guidelines provide some broad directions to diagnosis and management, they lack clarity on irAE-specific symptom evaluation and work-up, as well as assessment of severity. These limitations can then impact triage, time-sensitive management and care escalation to specialists such as oncoendocrinologists. The objective of this study was to develop consensus-based statements on disease definitions for E-irAEs. A core working group of endocrinologists with expertise in the oncoendocrinology field drafted a survey with statements outlining the general approach to E-irAEs, disease definition and management approach of six specific diagnoses: ir-thyroiditis thyrotoxic phase, ir-thyroiditis hypothyroidism, ir-Graves’ disease, ir-hypophysitis, ir-adrenalitis and ir-type 1 diabetes mellitus. Severity grading tables were drafted for three disease categories—“thyroid”, “pituitary and adrenal”, and “diabetes mellitus”. A two-round modified Delphi process, using the RAND/University of California Los Angeles (RAND/UCLA) Appropriateness Method, was employed. In this process, a 25-member voting panel consisting of endocrinologists, oncologists and other specialists and healthcare providers with experience in management of ICI-treated patients and irAEs was recruited. The panel rated anonymously on usability, accuracy, appropriateness or agreement of 41 items on a 9-point scale in Survey 1, after which a meeting was convened. Statements were modified based on voting results from Survey 1 and Meeting 1, and the process was repeated in Survey 2 and Meeting 2. At the end of this process, consensus was achieved for all statements. Our study findings address the gap in standardized nomenclature, clinical, laboratory and radiological evaluations, and management principles of E-irAEs. With consensus achieved from a panel of experts from a variety of disciplines, we anticipate that the statements can form the basis for standardization of the diagnostic process and improvement of patient care.
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial
Giamarellos‐Bourboulis, Evangelos J. , Jemec, Gregor B. E. , Prens, Errol P. , Riedemann, Niels C. , Otto, Isabella , Weisman, Jamie, Pulka, Grażyna, Nowicki, Roman , Kantardjiev, Vessel, Pinter, Andreas , Berneman, Debra, Breno, Brigitte, Stone, Melody L., Anadkat, Milan J. , Papakonstantis, Markos, Bécherel, Pierre‐André, Szepietowski, Jacek C. , Nowicki, Roman J , Thomsen, Simon Francis , Kanni, Theodora , Alavi, A , Gooderham, Melinda J , Anadkat, Milan J , Katoulis, Alexandros , Papakonstantis, Markos , Becherel, Pierre-André , Szepietowski, Jacek C , van der Zee, Hessel H , Zouboulis, Christos C , Sayed, Christopher , Jemec, G B E , Pinter, A , Giamarellos-Bourboulis, Evangelos J , Otto, Isabell, Alavi, Afsáneh , Gooderham, Melinda , Zee, Hessel H. van der , Zouboulis, Christos C. , Sayed, Christopher J.

Mayo Clinic

British Journal of Dermatology | October 10, 2025 | Volume: 194 | Issue: 2 | Pages: 254-263

10.1093/bjd/ljaf398 | PMID 41081529 Get It

Abstract Background The results of a previous phase IIa trial suggested efficacy of the anti-C5a compound vilobelimab in a small number of patients with severe hidradenitis suppurativa (HS) refractory to adalimumab treatment. Objectives To study the efficacy of vilobelimab in a larger-scale randomized phase IIb trial (SHINE) of patients with moderate-to-severe HS. Methods In total, 177 patients with moderate-to-severe HS were treated either with placebo or one of four doses of vilobelimab, a monoclonal antibody that targets the complement split product C5a. Hidradenitis Suppurativa Clinical Response (HiSCR) at 16 weeks was the primary endpoint. Those who achieved HiSCR switched to open-label low-dose vilobelimab; those who did not were switched to medium-dose vilobelimab. The trial was registered with the EU Clinical Trials Register (EudraCT number 2017-004501-40) and ClinicalTrials.gov (NCT03487276). Results The study did not meet the primary endpoint, perhaps due, in part, to an unexpectedly high HiSCR placebo response rate of 47.1%. HS flares decreased and post hoc analysis showed that high-dose vilobelimab significantly decreased the median draining tunnel counts and IHS4 score by 63%. Following the switch to medium-dose vilobelimab at week 16, 45.5% of those who did not respond to treatment achieved HiSCR at week 40. Conclusions Compared with placebo, vilobelimab treatment did not result in significant HiSCR improvements in patients with moderate-to-severe HS. Post hoc analysis revealed significant effects for the highest tested dose on draining tunnel reduction and IHS4 score, which captures reductions in draining tunnels. These findings warrant further investigation.
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Garsed, Dale W. , Pandey, Ahwan , Ariyaratne, Dinuka , Laumont, Céline M. , Hamilton, Phineas T. , Alsop, Jennifer , Antoniou, Antonis C. , Au‐Yeung, George , Beckmann, Matthias W. , González, Amy Berrington de , Bisinotto, Christiani, Blome, Freya , Bodelón, Clara , Boros, Jessica , Brand, Alison H. , Carney, Michael E., Coulson, Penny , Cushing‐Haugen, Kara L. , Cybulski, Cezary, Darcy, Kathleen M. , David, C. W. Mabey, Davidson, Trent , Emons, Julius , Farrell, Rhonda , Gentry-Maharaj, Aleksandra, Harter, Philipp, Hartmann, Arndt, Heikaus, Sebastian, Hettiaratchi, Anusha , Heublein, Sabine , Huntsman, David G. , Jimenez-Linan, Mercedes , Jones, Michael E. , Kang, Eunyoung , Konecny, Gottfried E. , Kruitwagen, Rutgerus, Kwon, Jessica, Lambrechts, Diether , Lester, Jenny, Leung, Samuel , Leung, Yee , Loverix, Liselore , Mateoiu, Constantina , McNeish, Iain A. , Nevins, Nikilyn, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Quinn, Carmel M. , Mohan, Ganendra Raj , Ruebner, Matthias , Salfinger, Stuart , Samra, Spinder , Stewart, Colin J.R. , Talhouk, Aline , Tan, Adeline , Tarney, Christopher M., Aa, Maaike AVan Der, Gorp, Toon Van , Nieuwenhuysen, Els Van, Wagensveld, Lilian van , Wahner-Hendrickson, Andrea E., Walter, Christina B., Welz, Julia , Wentzensen, Nicolas , Winterhoff, Boris , Berchuck, Andrew, Fasching, Peter A. , Gayther, Simon A. , Kelemen, Linda E. , Maxwell, G. Larry , Menon, Usha , Modugno, Francesmary, Schildkraut, Joellen M. , Staebler, Annette , Swedlow, Anthony, Vergote, Ignace , Wu, Anna H. , Pearce, Celeste Leigh, Pike, M. C., Goode, Ellen L. , Bowtell, David D.L. , Lambrechts, Diether , Garsed, Dale W , Fereday, Sian , Pandey, Ahwan , Ariyaratne, Dinuka , Kennedy, Catherine J , Milne, Katy , Berrington de Gonzalez, Amy , Blome, Freya , Bodelon, Clara , Christie, Elizabeth L , Ekici, Arif B , Ghatage, Prafull , Hettiaratchi, Anusha , Jones, Michael E , Kommoss, Felix , Lambrechts, Diether , Lee, Cheng-Han , Leung, Yee , Linder, Anna , McNeish, Iain A , Nelson, Gregg S , Nevins, Nikilyn , Ray-Coquard, Isabelle L. , Roxburgh, Patricia , Van de Vijver, Koen , Wahner-Hendrickson, Andrea, Wang, Chen , Wentzensen, Nicolas , Winham, Stacey J , Anglesio, Michael S , Cohen, Paul , Conrads, Thomas , Fasching, Peter A , Horlings, Hugo , Karlan, Beth Y , Menon, Usha , Neuhausen, Susan L. , Brenton, James D , Pharoah, Paul D P , Goode, Ellen L , Ramus, Susan J , Köbel, Martin , Nelson, Brad H , Fazio, Anna de , Friedlander, Michael , Lambrechts, Diether , Brand, Alison H , Bowtell, David D , Goodman, Marc T , Zwimpfer, Tibor A. , Fereday, Sián , Jayawardana, Madawa , Twomey, Laura , Kennedy, Catherine J. , Bolithon, Adelyn , Meagher, Nicola S. , Milne, Katy , Cazorla, Alicia , Chiu, Derek S , Christie, Elizabeth L. , Chudecka-Glaz, Anita Monika , Ekici, Arif B. , Elishaev, Esther , Engler, Tobias , Fischer, Anna, García‐Closas, Montserrat , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Hartkopf, Andreas D , Hernandez, Brenda Y. , Kaznowska, Ewa B. , Kluz, Tomasz , Kruitwagen, Roy F.P.M. , Kwon, Jessica, Lee, Cheng‐Han , Lester, Jenny, Leung, Samuel, Linder, Anna , Lissowska, Jolanta , Lubiński, Jan , Moubarak, Malak , Nelson, Gregg , Olbrecht, Siel , Rodríguez‐Antona, Cristina , Schoemaker, Minouk J. , Sinn, Hans‐Peter , Sonke, Gabe S. , Steele, Linda, Taylor, Sarah E , Nieuwenhuysen, Els Van , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Anglesio, Michael S. , Reis, Francisco José Cândido dos , Cohen, Paul A. , Crowe, Philip John , Doherty, Jennifer A. , Fortner, Renée T. , García, María J. , Goodman, Marc T. , Gronwald, Jacek , Harris, Holly R. , Heitz, Florian , Karlan, Beth Y. , Sundfeldt, Karin , Brenton, James D. , Pharoah, Paul D.P. , Ramus, Susan J. , Köbel, Martin , Nelson, Brad H. , DeFazio, Anna , Friedländer, Michael

Mayo Clinic

No container title available | October 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7572112/v1 | PMID 41255967 Get It

Abstract BRCA-associated homologous recombination deficiency (HRD) is present in ~ 50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA-deficient tumors experience unexpectedly poor outcomes. We profiled 154 tumors, enriched for patients with BRCA-deficient tumors that experienced short overall survival (≤ 3 years, n = 42), using whole-genome, transcriptome, and methylation analyses. All but one BRCA-deficient tumor exceeded an accepted HRD genomic scarring threshold. However, patients with BRCA1-deficient HGSC with a more elevated HRD score survived significantly longer. Patients with BRCA2-deficient HGSC and loss of NF1 survived twice as long as those without NF1 loss, whereas PIK3CA or RAD21 amplification defined BRCA2-deficient HGSC with exceptionally short survival. BRCA1-deficient tumors in short survivors had evidence of immunosuppressive c-kit signaling and EMT. In a large HGSC cohort (n = 1,389) including 282 individuals with pathogenic germline BRCA variants (gBRCApv), the location of the mutation within functional domains stratified clinical outcomes. Notably, residual disease after primary surgery had limited prognostic effect in gBRCApv-carriers compared to non-carriers. Our findings indicate that tumor HR proficiency in the context of therapy response and survival is not a binary property, and highlight genomic and immune modifiers of outcomes in BRCA-deficient HGSC.
P108 Accuracy of auto-scored sleep for characterization of neurodegenerative disorder risk
Levendowski, Daniel J. , Bolengo, Francesca, Strambi, Luigi-Ferini, Galbiati, Andrea , Fischer, Corinne Eleanor , Berka, Chris , Lewis, Simon J.G. , Boeve, Bradley F. , Strambi, Luigi Ferini, Louis, Erik K. St.

Mayo Clinic

Sleep Advances | October 3, 2025 | Volume: 6 | Issue: Supplement_1 | Pages: A58-A59

10.1093/sleepadvances/zpaf053.168 Get It

Abstract Introduction This study investigated the impact of visual editing of sleep recordings for use in predicting neurodegenerative disorder (NDD) risk. Methods All participants underwent in-home Sleep Profiler studies. Forty-four were diagnosed with mild cognitive impartment (MCI = 40) or Alzheimer’s disease (AD = 4)(MCI/AD: 55% women, 72.6+/-8.6 years), 26 with REM sleep behavior disorder (RBD: women = 27%, age = 67+/-9.8), and 29 were controls (NC: women = 69%, age = 63+/-11.5). A 4-class machine learning algorithm used age plus eight sleep biomarkers to assign NDD risk probabilities. Records with CG-assigned probabilities &gt;70% were labeled Probably-Normal, and from 45-70% Likely-Normal. Similar thresholds were used to assign Likely- or Probably-Abnormal. NDD risk characterizations were generated based on auto-scoring (“auto”), and again after the recordings were visually edited for accuracy (“edited”). Results Comparing the auto- vs. edited-NDD classifications in the MCI/AD group, the same NDD risk classifications were observed in 91% (39/43), with 2 cases shifting from Likely-Normal to Probably-Normal, one shifted from Likely-AD to Likely-Normal with AD Indications, and one changed from Probably-AD to Likely-AD. The same NDD risk classifications were observed in 81% (21/26) of the RBD cases, 3 shifted from Probably-Abnormal to Likely-Abnormal, one shifted from Likely-Normal to Probably-Normal, and one changed from Likely-Abnormal to Likely-Normal. The same NDD risk classifications were observed in 86% of the NC group, with 4 cases shifting from Likely-Normal to Probably-Normal. Conclusions These findings suggest that the likelihood of a gross misclassification of NDD risk resulting from auto-detected sleep biomarkers is relatively low with inconsistencies directed toward slightly increased NDD risk classifications.
P107 Cultural differences in care for parents with a neurodegenerative disorder
Levendowski, Daniel J. , Strambi, L Ferini, Walsh, Christine M. , Neylan, TC, Lewis, Simon J.G. , Strambi, L Ferini, Fischer, Corinne Eleanor , Berka, Chris , Louis, Erik K. St.

Mayo Clinic

Sleep Advances | October 3, 2025 | Volume: 6 | Issue: Supplement_1 | Pages: A58-A58

10.1093/sleepadvances/zpaf053.167 Get It

Abstract Introduction This study investigated differences in opinions about neurodegenerative disorders (NDD) in countries with large populations and expanded access to healthcare. Methods A 5-point Likert scale survey assessed opinions of 30–59-year-olds, pertaining to their parents and NDD conditions. 100 surveys, translated into native languages, were acquired in eight developed countries. Positive (somewhat- or strongly-agree) vs. other responses, sex, and country were submitted to logistic regression and Chi-squared analyses. Results “It is important for me to know if my parent has a risk for developing a NDD condition in the future, even if nothing can be currently done to prevent or cure those diseases” had higher positive responses in Australia (92%) compared to Germany (74%) and the USA (78%). “I believe that knowing about my parent’s risk for developing a NDD condition will help me assist in the planning of their future” had higher number of positive responses in Australia (91%) versus Japan (70%), Germany (76%), Italy (80%) and UK (80%). “If my parent(s) was found to be at risk for a NDD condition, I would want to learn more about medications and adaptive therapies that could delay onset” was responded to more positively in Australia (92%), Canada (78%), France (87%), Germany (78%), Italy (88%), UK (88%), and USA (81%) versus Japan (60%). Conclusions Australians responded more positively to questions related to care of a parent with a NDD disorder. These findings suggest cultural differences that could influence education and support systems requirements for sleep medicine providers and NDD patients.
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
Mürdter, Thomas E. , Schroth, Werner , Goetz, Matthew P. , Igel, Svitlana , Schaeffeler, Elke , Jäger, Simon , Loibl, Sibylle , Gerteis, Andreas , Pfaff, Lena , Bechtner, Christina , Wrobel, Denise , Bernhoft, Inger Marie , Bernhöft, Ilka , Bjelic-Radisic, Vesna, Burkhardt, Michael , Darsow, Maren , Deutsch, Gerhard, Ts, Dewitz, Dietz, Wolfgang, Eichbaum, Michael, Faust, Elke, Göhler, Thomas, Graßhoff, Sven-Thomas, Hackmann, John , Hänle, Claudia, Hartkopf, A, Heinrich, Bernhard, Kahl, Christoph, Kaltenecker, Gabriele, Kleine-Tebbe, Anke, Hc, Kolberg, Krauss, Thomas, Kuhn, Thomas , Kunz, Georg , Ligl-Löhner, Anette, Negwer, Martina, Rhein, Uwe, Rogmans, Gunther, Rom, Joachim , Stalzer, Gabriele, Stefek, Andrea , Strittmatter, Hans-Joachim, Terhaag, Jürgen, Uleer, Christoph , Wimmer-Freys, Karen, Zahm, Dirk-Michael, Fischer, Imma , Meisner, Christoph , Block, Michael , Tremmel, Roman , Igel, Svitlana , Schaeffeler, Elke , Jäger, Simon , Loibl, Sibylle , Gerteis, Andreas , Pfaff, Lena , Bechtner, Christina , Wrobel, Denise , Fischer, Imma , Meisner, Christoph , Block, Michael , Brauch, Hiltrud , Schwab, Matthias , Goetz, Matthew P , Tremmel, Roman , Bjelic-Radisic, Vesna , Burkhardt, Michael, Hartkopf, Andreas D , Heinrich, Bernhard , Kleine-Tebbe, Anke, Krauß, Thomas, Kühn, Thomas, Schmatloch, Sabine , Schwab, Matthias , Strittmatter, Hans-Joachim, Zahm, Dirk-Michael, Brauch, Hiltrud

Mayo Clinic

Clinical Cancer Research | October 2, 2025 | Volume: 31 | Issue: 23 | Pages: 4903-4911

10.1158/1078-0432.ccr-25-2103 | PMID 41036998 Get It

Abstract Purpose :Tamoxifen undergoes bioactivation to its active metabolite (Z)-endoxifen, which blocks estrogen-dependent breast tumor growth at high potency. We tested the feasibility and safety of supplementing standard tamoxifen therapy with low-dose (Z)-endoxifen in patients with breast cancer with compromised tamoxifen bioactivation. Patients and Methods :We conducted a prospective, interventional, three group randomized trial including 235 patients with hormone receptor–positive breast cancer who received standard tamoxifen therapy (20 mg/day). Patients were stratified by CYP2D6 genotype (n = 78), defining poor, intermediate, and normal metabolizers, or by baseline (Z)-endoxifen plasma concentration (n = 78), defining ≤15, 15 to 25, and ≥25 nmol/L. Co-treatment with (Z)-endoxifen 3 and 1.5 mg/day or placebo was performed, respectively. A control group (n = 79) received placebo regardless of metabolizer phenotype. The primary endpoint was the number of patients with (Z)-endoxifen levels &gt;32 nmol/L after 6 weeks of treatment. Adverse events were continuously monitored. Results: A higher proportion of patients in both intervention groups achieved target concentrations &gt;32 nmol/L compared with control (P &lt; 0.0001). At 3 mg (Z)-endoxifen supplementation, 92.3% of CYP2D6 poor metabolizer patients and all patients with baseline (Z)-endoxifen ≤15 nmol/L achieved the target concentration. At 1.5 mg (Z)-endoxifen supplementation, 88% of CYP2D6 intermediate metabolizer patients and 95% of patients with 15 to 25 nmol/L baseline (Z)-endoxifen levels achieved the target concentration. Similar proportions of patients receiving (Z)-endoxifen (6/80, 7.5%) or placebo (8/155, 5.2%) experienced grade 3 adverse events. Conclusions: Adding low-dose (Z)-endoxifen to standard tamoxifen is safe and provides a new approach to personalized antiestrogen treatment for patients with low endoxifen plasma levels.
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2
Harding, James J. , Oh, Do‐Youn , Macarulla, Teresa , Goyal, Lipika , Varkaris, Andreas , Palmieri, Lola‐Jade , Ikeda, Masafumi , Kondo, Shunsuke , Bai, Li‐Yuan , Ueno, Makoto , Papadopoulos, Kyriakos P. , Shroff, Rachna T. , Kizilbash, Sani H. , Liao, Chih‐Yi , Azad, Nilofer S. , Jaeckle, Kurt A. , Bender, Mark H. , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B. , Gueorguieva, Ivelina , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiangyuan , Macarulla, Teresa , Chen, Li-Tzong , Papadopoulos, Kyriakos P , Shroff, Rachna T , Kizilbash, Sani H , Hollebecque, Antoine , Adeva, Jorge , Cosman, Rasha , Yokota, Tomoya , Park, Joon Oh , Turk, Anita , Liao, Chih-Yi , Satoh, Taroh , Borad, Mitesh J , El-Khouiery, Anthony B , Azad, Nilofer , Jaeckle, Kurt A , Loong, Herbert H , Yong, Wei-Peng , Bender, Mark H , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B , Gueorguieva, Ivelina , Szpurka, Anna M , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiaojian , Rodon, Jordi , Ikeda, Masafumi , Goyal, Lipika , Harding, James J , Chen, Li‐Tzong , Adeva, Jorge , Yokota, Tomoya , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Loong, Herbert H. , Yong, Wei Peng

Mayo Clinic

Clinical Cancer Research | September 30, 2025 | Volume: 31 | Issue: 23 | Pages: 4920-4932

10.1158/1078-0432.ccr-25-0174 | PMID 41026608 Get It

Abstract Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/IDH2-mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH-mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone (N = 94) or in combination with CISGEM (N = 19) or durvalumab (N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1- or IDH2-mutant cholangiocarcinoma or IDH1-mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH-mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2-mutated cholangiocarcinoma and IDH1-mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH-mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.
Poster 44: Outcomes of Revision Elbow Medial Ulnar Collateral Ligament Reconstruction in Professional Baseball Players: an Analysis of 191 Pitchers from 2010 to 2023
Chalmers, Peter N., Conte, Stan, Griffith, Timothy B. , Ma, Kevin , D’Angelo, John, Herbert, Liz, Simon, Karissa N. , Erickson, Brandon J. , Chalmers, Peter N. , Griffith, Timothy Bryan , D’Angelo, John, Herbert, Liz, Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00155 Get It

Objectives: The number of medial ulnar collateral ligament (MUCL) reconstructions are increasing. The epidemiology surrounding revision MUCL reconstructions in professional baseball players has not been well defined. The purpose of this study was to report the epidemiology of revision MUCL reconstruction in professional baseball players. The authors hypothesized that the number of revision MUCL reconstructions would increase over time and that the return to sport rate at the same level of play would be less than 70%. Methods: All professional baseball pitchers who underwent revision MUCL reconstruction between 2010-2023 were identified using the MLB Health and Injury Tracking System (HITS). Rate of return and time to return to play (RTP) and return to same level of play (RTSL) was recorded and analyzed for pitchers with a minimum follow up of 2 years. Surgical variables including technique and graft choice were also recorded. Results: Overall, 191 pitchers (avg age 26.0 years), underwent revision MUCL reconstruction. The average time between primary and revision surgery was 1,381 days (45 months). 130 (68%) of these players were MLB pitchers and the other 61 (32%) were MiLB pitchers. 59% of pitchers were able to RTSL at an average of 604 ± 250 days after surgery. 2023 was the year with most revision MUCL reconstructions (n = 27) and the fewest reconstructions were performed in 2010 and 2011 (n = 4). Monthly distribution demonstrates the highest surgery months to be May (17%), June (20%), and July (17%). Hamstring tendon autograft was found to be the most commonly used graft source (n = 90, 47%), compared to palmaris longus autograft (n = 67, 35%). No significant differences were found in the types of grafts used over time ( P = .238 for palmaris and P = .133 for hamstring). In terms of tunnel configuration, both the Modified Jobe and Docking techniques were used in equal occurrence (n = 70, 37%) Conclusions: Following revision MUCL reconstruction, only 72% of professional baseball pitchers were able to return to play at any level at an average of 556 days (18 months), and only 59% were able to return to the same level of play at an average of 604 days (20 months). The average time between primary and revision MUCL reconstruction was 45 months (3.75 years). Pitchers should be counseled on the relatively low RTSL rate and the prolonged time to RTSL.